Biotechnology News and Research

RSS

Lubricin injections can reduce cartilage degeneration

Medical researchers will report findings today (Oct. 19) that demonstrate that injecting the protein lubricin into knee joints can dramatically reduce cartilage degeneration.

19 Oct 2009

New 3D scaffolding technology may help grow skin and blood vessels in labs

Scientists are developing new scaffolding technology which could be used to grow tissues such as skin, nerves and cartilage using 3D spaghetti-like structures. Their research is highlighted in the latest issue of Business, the quarterly highlights magazine of the Biotechnology and Biological Sciences Research Council (BBSRC).

19 Oct 2009

First high-throughput analysis of Salmonella Typhi gene

For the first time, researchers are able to look at the need for every gene in a bacterial cell in a single experiment. The new method will transform the study of gene activity and the search for weaknesses in bacterial armouries.

19 Oct 2009

Preclinical data of carfilzomib and PR-957 inhibitors to be presented at 2009 ACR/ARHP meeting

Proteolix, Inc. today announced that data from preclinical studies of carfilzomib and PR-957 will be presented at the 2009 ACR/ARHP Annual Scientific Meeting on October 16 - 21 in Philadelphia, PA.

19 Oct 2009

Immune-related proteins are potential drug targets for gastric inflammation and cancer

A research team from South Korea studied the complex reaction of gastric inflammation induced by Helicobacter pylori (H pylori) in a systematic manner using a protein interaction network. Their study will be published on September 28, 2009 in the World Journal of Gastroenterology.

19 Oct 2009

Pfizer announces it has combined operations with Wyeth following the closing of the acquisition

Pfizer Inc today announced that it has combined operations with Wyeth following the closing of the acquisition yesterday. Pfizer is now a more diversified health care company, with product offerings in human, animal, and consumer health, including vaccines, biologics, small molecules and nutrition across the developed and emerging markets.

19 Oct 2009

Angiochem announces results of Phase 1 /2 clinical trials of ANG1005

Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases.

19 Oct 2009

Rituxan's sBLA receives a Complete Response from the FDA

Genentech, Inc. a wholly-owned member of the Roche Group, and Biogen Idec announced today that the companies received a Complete Response from the U.S. Food and Drug Administration (FDA) for a supplemental Biologics License Application (sBLA) for Rituxan (rituximab) plus methotrexate (MTX) in patients with moderately-to-severely active rheumatoid arthritis (RA) who no longer respond to treatment with a disease modifying antirheumatic drug (DMARD), including MTX.

19 Oct 2009

Clemson University receives a $9.3M NIH grant to establish a tissue regeneration center

Clemson University has received a $9.3 million, five-year National Institutes of Health (NIH) grant to establish a Center of Biomedical Research Excellence (COBRE) for Tissue Regeneration. Faculty from the Medical University of South Carolina and the University of South Carolina also will collaborate, providing expertise in medicine and developmental biology.

19 Oct 2009

Biogen Idec and Biovitrum to conduct rFIXFc clinical trial in hemophilia B patients

Biogen Idec and Biovitrum AB (STO: BVT) today announced that they plan to advance the companies’ long-acting, fully-recombinant Factor IX Fc fusion protein (rFIXFc) into a registrational clinical trial in hemophilia B patients.

19 Oct 2009

Update from Cardiome Pharma regarding its tender offer

Cardiome Pharma Corp. announced the final results of its modified "Dutch Auction" tender offer to purchase for cancellation up to US$27.5 million of its common shares (the "Offer"), which expired at 5:00 p.m. (Eastern time) on October 13, 2009.

19 Oct 2009

Gates Foundation to announce grants to promote agriculture at world food prize symposium

During a "keynote speech" Thursday at the World Food Prize Symposium in Des Moines, Iowa, Bill Gates, cofounder of the Bill & Melinda Gates Foundation, is expected to announce $120 million in grants "to promote dynamic, home-grown, sustainable agriculture in Africa and India,"

19 Oct 2009

Cancer Therapeutics and Nanotherapies sign letter of intent

Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today it has signed a letter of intent to acquire another 26 percent interest in NanoTherapies, LLC which would give Cancer Therapeutics a total of 51 percent and controlling interest of NanoTherapies.

19 Oct 2009

New EVestG diagnostic technique aids in quick detection of mental and neurological illnesses

An innovative diagnostic technique invented by a Monash University researcher could dramatically fast-track the detection of mental and neurological illnesses.

19 Oct 2009

CK Life Sciences acquires additional voting shares of WEX Pharmaceuticals

CK Life Sciences Int'l., (Holdings) Inc. ("CKLS") of Hong Kong (Hong Kong Stock Exchange Limited Stock Code 0775) and WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) announced today that CKLS has acquired an additional 116,852,062 restricted voting shares of WEX to bring its holding to 133,179,334 restricted voting shares, or 75.25% of the total outstanding restricted voting shares.

19 Oct 2009

Overview of innovative technology for treating ischemic and autoimmune disorders

Pluristem Therapeutics Inc. today announced that it will present at the New England-Israel Life Sciences Summit at the Brandeis International Business School in Waltham, Mass. Zami Aberman, chairman and CEO of Pluristem will present an update on the company and an overview of its technology at 9:40 EDT, Oct 27, 2009.

15 Oct 2009

Soligenix commences enrollment in its Phase 3 Orbec clinical trial for acute GI GVHD

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has initiated enrollment in its confirmatory Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial evaluating orBec(®) for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD).

15 Oct 2009

Biotechnology News and Research

Lubricin injections can reduce cartilage degeneration

New 3D scaffolding technology may help grow skin and blood vessels in labs

First high-throughput analysis of Salmonella Typhi gene

Preclinical data of carfilzomib and PR-957 inhibitors to be presented at 2009 ACR/ARHP meeting

Immune-related proteins are potential drug targets for gastric inflammation and cancer

Pfizer announces it has combined operations with Wyeth following the closing of the acquisition

Angiochem announces results of Phase 1 /2 clinical trials of ANG1005

Rituxan's sBLA receives a Complete Response from the FDA

Clemson University receives a $9.3M NIH grant to establish a tissue regeneration center

Biogen Idec and Biovitrum to conduct rFIXFc clinical trial in hemophilia B patients

Update from Cardiome Pharma regarding its tender offer

Gates Foundation to announce grants to promote agriculture at world food prize symposium

Cancer Therapeutics and Nanotherapies sign letter of intent

New EVestG diagnostic technique aids in quick detection of mental and neurological illnesses

CK Life Sciences acquires additional voting shares of WEX Pharmaceuticals

Overview of innovative technology for treating ischemic and autoimmune disorders

Soligenix commences enrollment in its Phase 3 Orbec clinical trial for acute GI GVHD

Baxter International announces financial results for third quarter 2009; updates full-year financial outlook

Positive results from Protalix BioTherapeutics Phase III UPLYSO clinical trial

BNA Books publishes the 2009 Cumulative Supplement to Pharmaceutical Patent Law

Biotechnology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News